Tom Strange
Private Equity Investor at iCON Infrastructure LLP
Tom Strange active positions
| Companies | Position | Start | End |
|---|---|---|---|
iCON Infrastructure LLP
 iCON Infrastructure LLP Investment ManagersFinance iCON Infrastructure LLP is a private equity firm founded in 2004 by Paul Malan. The firm is headquartered in London, United Kingdom with offices in Germany, Canada and the United States. | Private Equity Investor | 2023-05-31 | - |
Career history of Tom Strange
Former positions of Tom Strange
| Companies | Position | Start | End |
|---|---|---|---|
MiroBio Ltd.
 MiroBio Ltd. BiotechnologyHealth Technology Mirobio Ltd. operates as a biologics company focusing on autoimmune and inflammatory disorders. The firm develops antibody modulators of immune cell receptors, an approach that has potential across a range of diseases, with an initial focus on auto-immune disease. The company was founded by Richard Cornall and Simon Davis on October 8, 2018 and is headquartered in Oxford, the United Kingdom. | Private Equity Investor | 2022-03-31 | 2022-10-31 |
Training of Tom Strange
| University of Cambridge | Graduate Degree |
| The University of Nottingham | Undergraduate Degree |
Statistics
International
| United Kingdom | 4 |
| United States | 2 |
Operational
| Private Equity Investor | 2 |
| Graduate Degree | 1 |
| Undergraduate Degree | 1 |
Sectoral
| Consumer Services | 3 |
| Finance | 2 |
| Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
iCON Infrastructure LLP
iCON Infrastructure LLP Investment ManagersFinance iCON Infrastructure LLP is a private equity firm founded in 2004 by Paul Malan. The firm is headquartered in London, United Kingdom with offices in Germany, Canada and the United States. | Finance |
MiroBio Ltd.
MiroBio Ltd. BiotechnologyHealth Technology Mirobio Ltd. operates as a biologics company focusing on autoimmune and inflammatory disorders. The firm develops antibody modulators of immune cell receptors, an approach that has potential across a range of diseases, with an initial focus on auto-immune disease. The company was founded by Richard Cornall and Simon Davis on October 8, 2018 and is headquartered in Oxford, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Tom Strange
- Experience
